-- Update from Ongoing Phase 1 Clinical Trial of EO-3021 Now Expected Mid-2024 ---- Expanding EO-3021 Clinical Development Program to Include Combination Strategy -- -- Announcing HER3-targeting ADC ...
BOSTON, April 8, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results